Sjogren's Syndrome Clinical Trial Pipeline Gains Momentum: 10+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

DelveInsight's, "Sjogren's Syndrome Pipeline Insight 2026" report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Sjogren's Syndrome pipeline landscape. It covers the Sjogren's Syndrome Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Sjogren's Syndrome Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Sjogren's Syndrome Pipeline? Click here to explore the therapies and trials making headlines @ https://www.delveinsight.com/sample-request/sjogrens-syndrome-pipeline-insight [https://www.delveinsight.com/sample-request/sjogrens-syndrome-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Sjogren's Syndrome Pipeline Report

* On February 17, 2026, Immunovant Sciences GmbH announced a phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Primary Sjogren's Disease With Moderate to Severe Systemic Disease Activity.
* On February 13, 2026- Janssen Research & Development LLC conducted a study is to evaluate the clinical efficacy and safety of nipocalimab in participants with moderate to severe Sjogren's disease (SjD). This clinical development program for nipocalimab in SjD includes 2 identical double blind, placebo-controlled studies to evaluate the efficacy, safety, and tolerability of nipocalimab in participants greater than or equal to (>=) 18 years of age with moderate to severe SjD.
* On February 12, 2026- Amgen initiated a Study to Evaluate the Safety and Tolerability of Dazodalibep in Participants With Sjogren's Syndrome (SS).
* DelveInsight's Sjogren's Syndrome Pipeline report depicts a robust space with 10+ active players working to develop 12+ pipeline therapies for Sjogren's Syndrome treatment.
* The leading Sjogren's Syndrome Companies such as Johnson & Johnson, Novartis, Amgen, Artiva Biotherapeutics, Immunovant Sciences, Astellas Pharma Inc, RemeGen Co., Ltd., Rise Therapeutics LLC, Bristol-Myers Squibb, Argenx, Otsuka Pharmaceutical, Resolve Therapeutics, AbbVie and others.
* Promising Sjogren's Syndrome Therapies such as Baricitinib, Hydroxychloroquine, Nipocalimab, HZN-1116, RSLV-132, RO5459072, Lanraplenib, Filgotinib, Tirabrutinib, Belimumab, Iscalimab and others.

Want to know which companies are leading innovation in Sjogren's Syndrome? Dive into the full pipeline insights @ Sjogren's Syndrome Clinical Trials Assessment [https://www.delveinsight.com/sample-request/sjogrens-syndrome-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

The Sjogren's Syndrome Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Sjogren's Syndrome Pipeline Report also highlights the unmet needs with respect to the Sjogren's Syndrome.

Sjogren's Syndrome Overview

Sjogren's syndrome is a chronic autoimmune disorder in which the body's immune system mistakenly attacks its own moisture-producing glands, primarily the salivary and tear glands, leading to persistent dry eyes and dry mouth. Over time, the condition can also affect other organs, including the joints, skin, lungs, kidneys, and nervous system. It may occur alone (primary Sjogren's syndrome) or alongside other autoimmune diseases such as rheumatoid arthritis or lupus (secondary Sjogren's syndrome). Common symptoms include eye irritation, difficulty swallowing, fatigue, joint pain, and swollen salivary glands.

Sjogren's Syndrome Emerging Drugs Profile

* VAY736: Novartis

VAY736 (Ianalumab) is a novel, defucosylated, human IgG1/ monoclonal antibody that targets the human B cell-activating factor (BAFF) of the TNF family. The BAFF receptor is predominantly expressed on B cells and is critically involved in B cell maturation, activation, and survival. VAY736 targets the BAFF receptor and competitively inhibits BAFF binding to BAFF-R, thereby blocking BAFF-R-mediated signaling in B cells. It is also engineered to effectively eliminate B cells from circulation in vivo by antibody-dependent cellular cytotoxicity (ADCC). The ADCC activity of ianalumab is greatly enhanced by eliminating fucose residues from the carbohydrate moiety attached to the Fc part of the antibody. The molecule is being developed by Novartis in partnership with MorphoSys as an antibody-based therapy. The drug is currently in Phase III clinical studies for the treatment of Sjogren's Syndrome.

* Nipocalimab: Johnson & Johnson

IMAAVY is a monoclonal antibody, designed to bind with high affinity to block FcRn and reduce levels of circulating immunoglobulin G (IgG) antibodies that underlie generalized myasthenia gravis (gMG) without additional detectable effects on other adaptive and innate immune functions. The investigational monoclonal antibody is designed to bind with high affinity to block FcRn and reduce levels of circulating immunoglobulin G (IgG) auto and alloantibodies potentially without additional detectable effects on other adaptive and innate immune functions. The drugs has also been granted Breakthrough Therapy designation for for Sjogren's disease by the US FDA. Currently, the drug is in Phase III stage of its development for the treatment of Sjogren's syndrome.

* Allogeneic NK Cells: Artiva Biotherapeutics

AlloNK is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the ADCC effect of mAbs to drive B-cell depletion. AlloNK, as a non-genetically modified, non-targeted NK cell, is designed to utilize a mAb or NK engager for targeting, and therefore can be used in different combinations against different therapeutic targets. Currently, the drug is in Phase II stage of its development for the treatment of Sjogren's syndrome.

* ASP5502: Astellas Pharma Inc.

ASP5502 is an investigational small-molecule drug developed by Astellas Pharma, designed to inhibit the STING (Stimulator of Interferon Genes) pathway, which plays a crucial role in innate immune responses and is implicated in autoimmune conditions like primary Sjogren's syndrome. By targeting this pathway, ASP5502 aims to modulate the immune system's activity, potentially alleviating the chronic inflammation and glandular dysfunction characteristic of the disease. Notably, ASP5502 was identified through Astellas's innovative use of artificial intelligence in drug discovery, highlighting a modern approach to developing treatments for complex autoimmune disorders. Currently, the drug is in Phase I stage of its development for the treatment of Sjogren's syndrome.

If you're tracking ongoing Sjogren's Syndrome Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Sjogren's Syndrome Treatment Drugs [https://www.delveinsight.com/sample-request/sjogrens-syndrome-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

The Sjogren's Syndrome Pipeline report provides insights into:-

* The report provides detailed insights about companies that are developing therapies for the treatment of Sjogren's Syndrome with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Sjogren's Syndrome Treatment.
* Sjogren's Syndrome Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Sjogren's Syndrome Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Sjogren's Syndrome market.

Sjogren's Syndrome Companies

Johnson & Johnson, Novartis, Amgen, Artiva Biotherapeutics, Immunovant Sciences, Astellas Pharma Inc, RemeGen Co., Ltd., Rise Therapeutics LLC, Bristol-Myers Squibb, Argenx, Otsuka Pharmaceutical, Resolve Therapeutics, AbbVie and others.

Sjogren's Syndrome Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,

* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical

Sjogren's Syndrome Products have been categorized under various Molecule types such as,

* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy

From emerging drug candidates to competitive intelligence, the Sjogren's Syndrome Pipeline Report covers it all - check it out now @ Sjogren's Syndrome Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/sjogrens-syndrome-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Sjogren's Syndrome Pipeline Report

* Coverage- Global
* Sjogren's Syndrome Companies- Johnson & Johnson, Novartis, Amgen, Artiva Biotherapeutics, Immunovant Sciences, Astellas Pharma Inc, RemeGen Co., Ltd., Rise Therapeutics LLC, Bristol-Myers Squibb, Argenx, Otsuka Pharmaceutical, Resolve Therapeutics, AbbVie and others.
* Sjogren's Syndrome Therapies- Baricitinib, Hydroxychloroquine, Nipocalimab, HZN-1116, RSLV-132, RO5459072, Lanraplenib, Filgotinib, Tirabrutinib, Belimumab, Iscalimab and others.
* Sjogren's Syndrome Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Sjogren's Syndrome Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay ahead in Healthcare Research - discover what's next for the Sjogren's Syndrome Treatment landscape in this detailed analysis @ Sjogren's Syndrome Emerging Drugs and Major Players [https://www.delveinsight.com/sample-request/sjogrens-syndrome-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Contents

* Introduction
* Executive Summary
* Sjogren's syndrome: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Sjogren's syndrome- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* VAY736: Novartis
* Mid Stage Products (Phase II)
* Allogeneic NK Cells: Artiva Biotherapeutics
* Early Stage Products (Phase I)
* ASP5502: Astellas Pharma Inc
* Preclinical and Discovery Stage Products
* Inactive Products
* Sjogren's syndrome Key Companies
* Sjogren's syndrome Key Products
* Sjogren's syndrome- Unmet Needs
* Sjogren's syndrome- Market Drivers and Barriers
* Sjogren's syndrome- Future Perspectives and Conclusion
* Sjogren's syndrome Analyst Views
* Sjogren's syndrome Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=sjogrens-syndrome-clinical-trial-pipeline-gains-momentum-10-companies-lead-the-charge-in-pioneering-new-treatments-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/sjogrens-syndrome-pipeline-insight

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.